A Prospective Study of a Mosaic Embryo Transfer

Launched by COLORADO CENTER FOR REPRODUCTIVE MEDICINE · Jul 13, 2020

Keywords

ClinConnect Summary

This clinical trial is looking at how effective it is to transfer a type of embryo called a mosaic embryo in women dealing with infertility. A mosaic embryo has a mix of both normal and abnormal cells, and the study aims to see how this impacts pregnancy outcomes after being screened for genetic issues. The research is currently recruiting women who are between the ages of 18 and 45 and have already gone through an in vitro fertilization (IVF) cycle at the Colorado Center for Reproductive Medicine (CCRM) where they found a mosaic embryo. Participants must be open to transferring just one embryo.

To join the study, women need to be struggling with infertility and meet specific health requirements for embryo transfer. The trial welcomes patients of all backgrounds, as long as they have completed their IVF cycle at CCRM and have a mosaic embryo. It's important to note that women who want to transfer more than one embryo or who are using a gestational carrier are not eligible. Participants will have the opportunity to contribute to important research that could help others facing similar challenges in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women age 18-45 Infertile women who have completed an IVF cycle with PGT at the Colorado Center for Reproductive Medicine (CCRM) that have a mosaic embryo
• • Patients can be of any race, culture, sexual orientation or ethnicity
• • Patients that are willing to transfer a single embryo
• Exclusion Criteria:
• • Patients that do not meet the clinical requirements for an embryo transfer per clinic standards.
• • Patients that desire more than a single embryo transfer.
• • Patients that are using a gestational carrier.
• • Embryonic mosaic PGT results that include chromosome errors 13, 18, 21
• • Patients that did not complete their IVF with PGT cycle at the Colorado Center for Reproductive Medicine.